Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

NCT07675057 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms
Neoplasm Metastasis
Carcinoma, Transitional Cell

Interventions

DRUG: Vepugratinib

Sponsor

Eli Lilly and Company